Purpose: To identify systemic risk factors associated with treatment failure of diode laser photocoagulation for threshold or prethreshold retinopathy of prematurity (ROP).
Methods: Consecutive infants treated with laser at our institution and infants referred from outside centers with progression to stage 4 or 5 ROP after laser treatment were included in this retrospective study. Two groups were identified: those with regression of ROP after laser (LT group; 196 eyes of 98 infants) and those with progression to stage 4 or 5 ROP after laser (ST group; 134 eyes of 80 infants).
Results: Using a multiple logistic regression model, there was a statistically significant association for progression of treated ROP to retinal detachment (RD) with history of sepsis (P < 0.001), oxygen therapy (P = 0.003), mechanical ventilation (P = 0.003), respiratory distress syndrome (RDS; P = 0.005), and patent ductus arteriosus (PDA; P = 0.042). On the other hand, jaundice (P = 0.563), anemia (P = 0.599), thrombocytopenia (P = 0.689), and blood transfusion (P = 0.878) did not show a statistically significant association with failure of laser treatment and progression of ROP to stage 4 or 5 disease.
Conclusions: Premature infants with a history sepsis, oxygen therapy, mechanical ventilation, RDS, and PDA may be at a higher risk for progression of ROP despite diode laser treatment.
Anilido-oxazoline-ligated iron complexes, including bis(anilido-oxazolinate) iron(II), mononuclear iron(II) alkyl and aryloxide, as well as the dinuclear analogues, were synthesized, and their catalytic performance on ring-opening polymerization (ROP) has been studied. Transmetalation of FeCl(THF) with in situ-generated anilido-oxazolinate lithium afforded the bis(anilido-oxazolinate) iron complexes and . Half-sandwich anilido-oxazolinate iron trimethylsilylalkyl complexes and could be synthesized in good yields via taking pyridine as an L-type ligand.
Retinopathy of prematurity (ROP) remains a significant health care concern in neonatal care as advances in neonatal intensive practices have improved the survival rates of premature infants. The management and screening of ROP have evolved significantly, with notable trends and advancements aimed at improving outcomes. The use of intravitreal antivascular endothelial growth factor injections has emerged as a prominent initial treatment for ROP in addition to laser photocoagulation.
Aim: Evaluation of screening and treatment of retinopathy of prematurity (ROP) at the Department of Pediatric Ophthalmology.
Material And Methods: Retrospective evaluation of the medical records of premature babies, born in the period 2012-2022 and treated at the Neonatology Department and the Neonatology ICU at the University Hospital Brno. On average 150 children annually are put forward for screening of ROP.
Purpose: To evaluate the foveal development in patients diagnosed with retinopathy of prematurity (ROP) and to evaluate whether foveal development was affected by treatment in ROP patients.
Methods: This cross-sectional study included patients with a history of ROP. Foveal development was compared between eyes with spontaneous regression and treated eyes.
